Transplant glomerulopathy

Signs and symptoms

Transplant glomerulopathy (TG) may present as clinically silent and only be detected on biopsy.

Low-level proteinuria and/or a slight decline in glomerular filtration rate are examples of early clinical manifestations. However, as the lesion worsens, hypertension, a drop in glomerular filtration rate, and an increase in proteinuria, often into the nephrotic range, may occur.

Complications

Numerous studies have linked reduced allograft survival to transplant glomerulopathy.

Causes

TG is thought to be a morphologic expression of chronic antibody-mediated rejection (ABMR) in most cases and is well-documented as being correlated with a buildup of donor-specific antibodies (DSAs), particularly against HLA class II antigens. But TG is not exclusive to chronic ABMR; in one-third to one-fourth of cases, thrombotic microangiopathy (TMA), hepatitis C, and possibly T cell-mediated rejection (TCMR) appear to be the alternative etiologies.

Mechanism

Transplant glomerulopathy (TG) is a slowly developing, long-lasting damage to the glomerular capillary walls that is thought to result from long-term glomerular endothelial activation and injury. The glomerular basement membrane is also repaired and remodeled in conjunction with this condition. Reduced podocyte density and glomerular epithelial cell stress are also factors in transplant-related glomerular injury, which includes increased urine podocyte excretion in TG and significant podocyte detachment, both of which are linked to progressive glomerulosclerosis.

Out of all the suggested mechanisms, the one that has been documented the most is the correlation between donor-specific antibody against the human leukocyte antigen (anti-HLA-DSA), antibody-mediated mediated rejection (ABMR), and endothelial damage that results in the development of TG.

Clinical investigations have also demonstrated the connection between TG and humoral alloimmunity.TG is first thought to be the characteristic lesion of chronic ABMR. Compared to other transplants, HLA-incompatible transplants that need to be desensitized have a higher prevalence of TG. Patients with TG have consistently been found to have an increased prevalence of donor-specific anti-HLA antibodies (DSA) and an increased incidence of antecedent or concurrent ABMR. Apart from preformed DSA, de novo DSA development has also been linked to TG, indicating that pathogenetic relevance to TG also extends to either new or recurrent endothelial damage resulting from de novo DSA.

The most compelling evidence for the theory that non-HLA antibodies could cause ABMR has come from studies on HLA identical renal allograft recipients who developed anti-donor endothelial reactive antibodies. According to data, non-HLA auto- and alloantibodies may contribute to chronic graft loss either by themselves through cytotoxicity or in conjunction with anti-HLA antibodies.

Clinical biopsy studies showing TG lesions in the absence of discernible acute or chronic ABMR have raised the possibility that non-humoral mechanisms may be responsible for the TG pathogenesis in these cases.

It has long been believed that humoral immunity is the cause of microvascular inflammation (MVI), which occurs in conjunction with TG and ABMR.

Diagnosis

Transplant glomerulopathy (TG) is best recognized histologically by reduplications or "double contours" of the glomerular basement membrane in peripheral glomerular capillary loops; basement membrane stains (methanamine silver and periodic acid-Schiff) work best for this kind of identification. Since it is a focal lesion in the early stages and only affects a small percentage of glomeruli, sufficient glomerular sampling is required. The lesion becomes more diffuse over time, accompanied by secondary focal segmental and global glomerulosclerosis and hyalinosis, variable mesangial matrix expansion (without the formation of mesangial nodules or significant mesangial cell proliferation), and associated glomerular hypertrophy. Severe nodular hyaline arteriolosclerosis, arterial fibrous intimal thickening, and progressive interstitial fibrosis and tubular atrophy are typically linked to advanced TG.

According to the Banff '97 criteria, double contours had to be present in at least 10% of the capillary loops in the most affected glomerulus in order to diagnose transplant glomerulopathy.

Immunofluorescence (IF) results for TG show no diagnostic staining for IgG, IgA, or C1q, as well as mild-to-moderate glomerular mesangial along with capillary wall deposition of IgM and C3.

Differential diagnosis

Differential diagnosis (DDX) of transplant glomerulopathy includes thrombotic microangiopathies, recurrent membranoproliferative glomerulonephritis, and ischemia.

Treatment

The general management of patients with TG involves renin-angiotensin-aldosterone (RAAS) blockade, blood pressure and diabetes control, weight loss, and other strategies to lower intra-glomerular pressure.

References

References

1. Haas, Mark. (2015). "Transplant Glomerulopathy". Ovid Technologies (Wolters Kluwer Health).
2. (July 10, 2009). "Transplant Glomerulopathy: Morphology, Associations and Mechanism". S. Karger AG.
3. (2007). "Transplant Glomerulopathy: Subclinical Incidence and Association with Alloantibody". Elsevier BV.
4. (2018). "Transplant glomerulopathy". Elsevier BV.
5. (November 27, 2005). "The Clinical Impact of Chronic Transplant Glomerulopathy in Cyclosporine Era". Ovid Technologies (Wolters Kluwer Health).
6. (2009). "Combination of Peritubular C4d and Transplant Glomerulopathy Predicts Late Renal Allograft Failure". Ovid Technologies (Wolters Kluwer Health).
7. (September 15, 2008). "Transplant Glomerulopathy: Risk and Prognosis Related to Anti-Human Leukocyte Antigen Class II Antibody Levels". Ovid Technologies (Wolters Kluwer Health).
8. (2015). "Donor-Specific Antibodies, C4d and Their Relationship With the Prognosis of Transplant Glomerulopathy". Ovid Technologies (Wolters Kluwer Health).
9. Haas, Mark. (2015). "Transplant Glomerulopathy". Ovid Technologies (Wolters Kluwer Health).
10. (2007). "Transplant Glomerulopathy, Late Antibody-Mediated Rejection and the ABCD Tetrad in Kidney Allograft Biopsies for Cause". Elsevier BV.
11. (2015). "The Two Kidney to One Kidney Transition and Transplant Glomerulopathy". Ovid Technologies (Wolters Kluwer Health).
12. (February 6, 2021). "Chronic transplant glomerulopathy: New insights into pathogenesis". Wiley.
13. (March 15, 2014). "Histologic Phenotype on 1-Year Posttransplantation Biopsy and Allograft Survival in HLA-Incompatible Kidney Transplants". Ovid Technologies (Wolters Kluwer Health).
14. (2006). "Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation". Elsevier BV.
15. (2009). "Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies". Elsevier BV.
16. (2012). "Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant". Elsevier BV.
17. (1982). "Hyperacute Rejection of Hla-Ab-Identical Renal Allografts Associated with B Lymphocyte and Endothelial Reactive Antibodies". Ovid Technologies (Wolters Kluwer Health).
18. Opelz, Gerhard. (2005). "Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies". Elsevier BV.
19. (2007). "Transplant Glomerulopathy May Occur in the Absence of Donor-Specific Antibody and C4d Staining". Ovid Technologies (Wolters Kluwer Health).
20. (2016). "Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts". Elsevier BV.
21. Gibson, Ian W.. (March 30, 2021). "Transplant Glomerulopathy: Importance of Ultrastructural Examination". S. Karger AG.
22. (1999). "The Banff 97 working classification of renal allograft pathology". Elsevier BV.
23. (2008). "Transplant Glomerulopathy". Elsevier BV.